|
gptkbp:instanceOf
|
antidepressant
norepinephrine reuptake inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AX21
|
|
gptkbp:brand
|
gptkb:Cymbalta
Irenka
|
|
gptkbp:CASNumber
|
116539-59-4
|
|
gptkbp:cause
|
gptkb:orthostatic_hypotension
hypertension
liver toxicity
suicidal thoughts (in young adults)
|
|
gptkbp:chemicalFormula
|
gptkb:C18H19NOS
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
uncontrolled narrow-angle glaucoma
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
duloxetine
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:MAO_inhibitors
CYP2D6 inhibitors
CYP1A2 inhibitors
other serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
297.42 g/mol
|
|
gptkbp:patentExpired
|
2013 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:riskOfSerotoninSyndrome
|
yes
|
|
gptkbp:riskOfWithdrawalSymptoms
|
yes
|
|
gptkbp:sideEffect
|
nausea
constipation
fatigue
loss of appetite
drowsiness
dry mouth
sexual dysfunction
increased sweating
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
fibromyalgia
chronic musculoskeletal pain
diabetic peripheral neuropathic pain
stress urinary incontinence
|
|
gptkbp:bfsParent
|
gptkb:Cymbalta
|
|
gptkbp:bfsLayer
|
6
|